Senti Biosciences, INC Schedule 13D activist filings

Celadon Partners SPV 35 Limited is set to acquire Senti Biosciences' Gene-Circuit pipeline, including SENTI-202, through a merger agreement, with Senti Biosciences Holdings, Inc. remaining a public entity.

Celadon Partners has increased its stake in Senti Biosciences to 54.6% through a significant investment in convertible notes, signaling a strategic shift for the gene therapy company.

Bayer HealthCare LLC and associated entities filed an amended Schedule 13D confirming a 17.82% beneficial ownership stake in Senti Biosciences, Inc.

New Enterprise Associates and affiliated entities report a decrease in their beneficial ownership of Senti Biosciences, Inc. common stock to 12.1% due to an increase in outstanding shares.

Celadon Partners, a significant shareholder in Senti Biosciences, is engaged in preliminary discussions for a potential $10 million convertible bond financing and strategic transactions.

Celadon Partners, holding 45% of Senti Biosciences, is in discussions for a potential financing deal and board representation, signaling strategic changes.

Bayer HealthCare LLC and Bayer US Holding LLC, along with their managers, have disclosed a combined 19.99% beneficial ownership stake in Senti Biosciences, Inc. following a strategic investment involving preferred stock conversion and warrant exercise.

Celadon Partners SPV 24 and Celadon Partners, LLC filed an Amendment No. 1 to their Schedule 13D for Senti Biosciences, Inc., solely to provide detailed information on their managers.

Celadon Partners SPV 24 has reported a 37.6% beneficial ownership stake in Senti Biosciences, Inc. after converting Series A Preferred Stock into 9,777,000 shares of common stock.

New Enterprise Associates (NEA) has reaffirmed its substantial 14.5% beneficial ownership in Senti Biosciences, Inc. following the conversion of Series A Preferred Stock into common shares.